fprl1

MMK 1 acetate is an agonist of formyl peptide receptor 2 (FPR2), which was previously known as formyl peptide receptor-like 1 (FPRL1) [1].

Ac9-25 acetate is an annexin AI peptide and activates the neutrophil reduced nicotinamide adenine dinucleotide phosphate oxidase through FPR but not through FPRL1.

WKYMVM is a N-formyl peptide receptor (FPR1) agonist.

WRW4-OH is a bioactive peptide that impedes the interaction of the FPRL1 agonist WKYMVm with its designated receptor. As a classical chemoattractant receptor prevalent in phagocytic cells of peripheral blood and brain, FPRL1's activation is integral to inflammatory responses within host defense mechanisms and is implicated in neurodegenerative disorders.

WKYMVM-NH2 is a hexapeptide that activates neutrophils and myeloid cells through the FPRL1 and FPRL2 receptors, with EC50 values of 2 nM for HL-60-FPRL1 cells and 80 nM for HL-60-FPRL2 cells. It also induces chemotaxis in HL-60 cells stably expressing FPRL2, with optimal migration observed at concentrations ranging from 10 to 50 nM. Additionally, WKYMVM-NH2 stimulates neutrophils to produce superoxide with an EC50 of 75 nM. It is applicable in research focused on inflammatory diseases.

WRW4 TFA (878557-55-2 free base) is a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC50 of 0.23 μM. WRW4 TFA(878557-55-2 free base) specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.

WRW4 TFA is a formyl peptide receptor-like 1 (FPRL1) antagonist that specifically prevents the binding of WKYMVm to FPRL1 with an inhibition concentration (IC50) of 0.23 μM. It uniquely blocks the rise in intracellular calcium triggered by FPRL1 agonists such as MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide [1].

WKYMVM-NH2 TFA, a potent agonist for N-formyl peptide receptor (FPR1) and FPRL1 2, activates key leukocyte effector functions including chemotaxis, complement receptor-3 mobilization, and NADPH oxidase activation, as documented in references [1] [2] [3].

RhB-PBP10 TFA, a Rhodamine B-labeled PBP10 TFA (FPR2 antagonist), selectively inhibits granule mobilization and oxygen radical secretion in FPRL1-induced neutrophils [1].